Evaluation of BI 1569912 on Pharmacokinetics of Repaglinide, Midazolam, and Bupropion in Healthy Volunteers

The primary objective of this study is to evaluate the influence of **BI 1569912** on the pharmacokinetics of **repaglinide**, **midazolam**, and **bupropion** in healthy male and female volunteers. Understanding the interaction between BI 1569912 and these drugs is clinically relevant as it may inform dosing adjustments and safety considerations when these medications are co-administered. This study is conducted in a healthy volunteer population to establish a baseline understanding of these interactions without the confounding effects of underlying health conditions.

The clinical trial involves a study population of **healthy volunteers**. The age range of participants is categorized under code "3", which typically includes adults. Both male and female subjects are included in the trial, indicating a gender-diverse participant pool. The trial also involves a **vulnerable population**, although specific details regarding this aspect are not provided. The sponsor has not disclosed the total number of participants involved in the study. Information regarding the selection process for the trial population, as well as any lifestyle considerations such as diet, physical activity, or habits, has not been provided. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed as a **randomized**, **double-blind**, and controlled study, focusing on healthy volunteers. The primary aim is to evaluate the influence of BI 1569912 on the pharmacokinetics of **repaglinide**, **midazolam**, and **bupropion** in the bloodstream. The trial is categorized under Phase 3, indicating advanced stages of testing prior to potential regulatory approval. The estimated recruitment start date is May 13, 2024, with an anticipated end date of August 23, 2024, marking the overall trial duration.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. This initial visit is crucial for determining eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study arms. Throughout the trial, several follow-up visits will be scheduled to monitor the participants' health status and collect necessary data on drug interactions. These visits are essential for ensuring participant safety and the integrity of the data collected. The trial will conclude with an end-of-study visit, where final assessments will be conducted, and participants will be debriefed.

The expected length of participant involvement spans from the recruitment phase through to the end-of-study visit, approximately three months. However, certain conditions may necessitate early termination from the study. These include adverse reactions to the investigational product, non-compliance with study protocols, or withdrawal of consent by the participant. The study is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the trial duration.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in the study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on May 13, 2024, with an estimated end date of August 23, 2024. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger population. The trial's design will likely include various tools and instruments to measure efficacy, consistent with clinical trial protocols, although these are not specified in the provided information.